Option Care Health, Inc.

Option Care Health is a U.S.-based provider of home and alternate-site infusion services delivered through a national network of locations. The company supplies infusion therapies, related pharmaceuticals, nursing support, and care coordination for patients with complex and chronic medical conditions, working under physician direction across the United States.

7,2 %

19,3 %

3,7 %

+13,0 %

1.53

0.96

— Option Care Health, Inc.
%
Infusion therapy services70% Administration of intravenous therapies in patients' homes or other nonhospital settings.
Pharmaceuticals and compounded solutions20% Medications and complex compounded products delivered as part of infusion care.
Nursing and clinical support10% Nursing visits, care coordination, and therapy management tied to infusion treatment.

Option Care Health serves patients needing infusion treatment for acute and chronic conditions, with care coordinated...

  • Patients requiring infusion therapyprimary

    Patients receiving IV therapies at home or other nonhospital settings for chronic and acute conditions.

  • Managed care organizations and third-party payersprimary

    Payers that authorize, reimburse, and steer patient access to home infusion services.

  • Physicians and referral sourcesprimary

    Physicians, discharge planners, and hospital staff that refer patients into the service network.

  • Hospitals and health systemssecondary

    Health systems that use the company for transitional and post-acute infusion care.

  • Pharmaceutical manufacturerssecondary

    Drug makers that rely on the company for distribution, launch support, and adherence programs.

Option Care Health operates primarily in the United States through a national network of locations across many states...

  • Operations are concentrated in the United States
  • National network supports patient access across many states
  • Location footprint matters for referral coverage and service speed
  • U.S. payer and reimbursement rules shape economics
  • No country-level revenue disclosure was provided in the excerpts

The company’s strategy centers on expanding relationships with drug manufacturers, managed care organizations, and...

01
Maintain and expand manufacturer partnershipsshort-term

Access to compatible therapies and launch opportunities supports patient volume and service breadth.

02
Grow payer and referral network coveragemedium-term

Managed care and referral relationships determine patient access and service flow.

03
Broaden complex therapy capabilitiesmedium-term

A wider therapy mix supports relevance across chronic and acute treatment categories.

The business is exposed to payer reimbursement pressure, drug supply dependence, and concentration in managed care...

high

Payer reimbursement pressure

Managed care organizations and government payers can reduce reimbursement rates or change coverage rules.

Scope
Home infusion and specialty pharmacy reimbursement
Materiality
high
high

Dependence on compatible pharmaceuticals

The business relies on manufacturers to supply drugs that fit home infusion administration requirements.

Scope
Drug supply, recalls, FDA changes, manufacturer strategy
Materiality
high
high

Managed care concentration

Loss of key payer relationships could reduce patient referrals and access to covered lives.

Scope
MCO and third-party payer contracts
Materiality
high
high

Cybersecurity and privacy incidents

The company stores protected health information and depends on secure IT systems for operations.

Scope
HIPAA data, patient records, billing systems
Materiality
high
medium

Billing audits and compliance reviews

Government and private payer audits can lead to adverse findings, repayments, or operational changes.

Scope
Claims, coding, reimbursement documentation
Materiality
medium
Revenue recognition and payer estimates
Net revenue and accounts receivable
Timing of pharmaceutical vs. nursing revenue
Quarterly revenue timing
Goodwill impairment
Potential non-cash impairment charges
Accounts receivable collectability
Bad debt and working capital

: 29.4.2026